Reset
Showing 6 of 26 academic articles

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

Wei Liu, Yan Xu, Yi Wang, Lugui Qiu et al. • Journal for ImmunoTherapy of Cancer (2024)

Background Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to achieve durable remission. Early identification of relapse or prog...

DOAJ Open Access (DOAJ) DOI: 10.1136/jitc-2023-008450

Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration

Katie S. Gatwood, Bhagirathbhai R. Dholaria, Mariana Lucena, Brittney Baer et al. • eJHaem (2022)

Abstract Adoptive cellular therapy has made a landmark change within the treatment paradigm of several hematologic malignancies, and novel cellular therapy products, such as chimeric antigen receptor T‐cell therapy (CART), have demonstrated...

DOAJ Open Access (DOAJ) DOI: 10.1002/jha2.333

Outcomes of primary gastrointestinal diffuse large B cell lymphoma in the rituximab era

Luyao Zhang, Jianwen Zhou, Yanyan Sun, Yaodong Zhang et al. • Discover Oncology (2026)

Abstract Background Primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) constitutes 30%-40% of primary extranodal lymphomas. While rituximab has significantly improved survival in nodal DLBCL, its impact on the prognosis of P...

DOAJ Open Access (DOAJ) DOI: 10.1007/s12672-026-05022-z

A New Strategy for Efficient Screening and Identification of Monoclonal Antibodies against Oncogenic Avian Herpesvirus Utilizing CRISPR/Cas9-Based Gene-Editing Technology

Man Teng, Zi-Yu Zhou, Yongxiu Yao, Venugopal Nair et al. • Viruses (2022)

Marek’s disease virus (MDV) is an important oncogenic α-herpesvirus that induces Marek’s disease (MD), characterized by severe immunosuppression and rapid-onset T-cell lymphomas in its natural chicken hosts. Historically, MD is regarded as ...

DOAJ Open Access (DOAJ) DOI: 10.3390/v14092045

Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case Report

Lars Kurch, Thomas W. Georgi, Astrid Monecke, Daniel Seehofer et al. • Frontiers in Oncology (2022)

A 28-year-old female patient with active and difficult-to-treat systemic lupus erythematosus (SLE) was diagnosed with liver-dominant diffused large B-cell lymphoma. Repeated response 18F-FDG-PET studies showed persistently high, and, despit...

DOAJ Open Access (DOAJ) DOI: 10.3389/fonc.2021.798757